분자유전학실험실 (단국대학교 분자생물학과)



 이성욱 ( 2018-08-19 18:57:50 , Hit : 146
 Lenvima OK'd as First-Line Treatment for Unresectable Hepatocellular Carcinoma

https://www.empr.com/news/lenvima-lenvatinib-hepatocellular-carcinoma-approved-hcc-liver-cancer/article/789154/


MPR >
News >
Lenvima OK'd as First-Line Treatment for Unresectable Hepatocellular Carcinoma

  


Da Hee Han, PharmD


August 16, 2018

The Food and Drug Administration (FDA) has approved Lenvima (lenvatinib; Eisai) as a first-line treatment for patients with unresectable hepatocellular carcinoma (HCC).

The approval was supported by findings from the multicenter, randomized, open-label, noninferiority trial, REFLECT (N=945), which included patients with previously untreated, metastatic or unresectable HCC. Study patients received Lenvima based on actual body weight or sorafenib until radiological disease progression or unacceptable toxicity.

Lenvima proved noninferior but not statistically superior to sorafenib for overall survival (hazard ratio [HR] 0.92, 95% CI, 0.79, 1.06). In the Lenvima arm, median overall survival was 13.6 months compared with 12.3 months in the sorafenib arm. Also, a statistically significant improvement in progression-free survival (PFS) was seen with Lenvima vs sorafenib (7.3 months vs 3.6 months; HR 0.64, 95% CI, 0.55, 0.75; P <.001) according to modified Response Evaluation Criteria in Solid Tumors (RECIST) for HCC. Moreover, the objective response rate was greater in the Lenvima arm compared with sorafenib (41% vs 12% per mRECIST; 19% vs 7% per RECIST 1.1).  



Related Articles
Keytruda sBLA Granted Priority Review for Advanced Hepatocellular Carcinoma
Positive Top-Line Results for Ramucirumab in HCC Announced
BMI Linked to Hepatocellular Carcinoma Risk in Chronic Hep B


Lenvima, a kinase inhibitor, is already indicated in combination with everolimus to treat advanced renal cell carcinoma, following one prior anti-angiogenic therapy; and to treat locally recurrent or metastatic, progressive, radioactive iodine-refractory differentiated thyroid cancer.

It is supplied as 4mg and 10mg strength capsules.

For more information call (877) 873-4724 or visit Lenvima.com.







1247   [바이오토픽] CRISPR 특허전쟁 항소심, 브로드 연구소 승리  이성욱 2018/09/11 128
  Lenvima OK'd as First-Line Treatment for Unresectable Hepatocellular Carcinoma  이성욱 2018/08/19 146
1245   [바이오토픽] 유전자를 침묵시키는 신약, 20년의 기다림 끝에 승인  이성욱 2018/08/13 166
1244   Doubts arise again about CRISR'd human embryos  이성욱 2018/08/09 158
1243   CRISPR-Cas12a More Precise Than CRISPR-Cas9  이성욱 2018/08/07 157
1242   Lethal Viruses Hijack DNA-Damage Response, May Be Exploited for Cancer  이성욱 2018/08/07 140
1241   Ruling on gene editing crops a threat to innovation and future food security, scientists say  이성욱 2018/07/28 132
1240   Another "CRISPR Calamity"? U.K. Team Reports CRISPR-Induced Gene Rearrangements  이성욱 2018/07/17 162
1239   Cause of CRISPR Failure Identified and Reversed  이성욱 2018/07/12 201
1238   CRISPR Efficiency Tied to Cancer-Causing Process  이성욱 2018/06/13 204
1237   Gene Therapy Ever More Common for Rare Disorders  이성욱 2018/05/30 214
1236   RNA World May Have Started Spinning with Triplet-Based Synthesis  이성욱 2018/05/21 197
1235   CRISPR’s MAGESTIC Evolution Makes Gene Editing More Precise  이성욱 2018/05/08 293
1234   CRISPR-Cas9 Improved 10,000-Fold by Synthetic Nucleotides  이성욱 2018/04/17 292
1233   Nature Methods retracts CRISPR study  이성욱 2018/04/10 493
1232   릴리 '시람자' 간암 말기 임상시험 성공  이성욱 2018/04/07 341
1231   Powerful enzyme could make CRISPR gene-editing more versatile  이성욱 2018/03/01 323
1230   Severe Toxicity Reported in High-Dose AAV Gene Therapy in Animals  이성욱 2018/02/01 517
1229   Shields Up for New Cancer Gene-Therapy Virus  이성욱 2018/02/01 407
1228   JPM서 논란 ‘유전자가위 기술’ 올해의 마일스톤은?  이성욱 2018/01/21 766

[1] 2 [3][4][5][6][7][8][9][10]..[64] [다음 10개]
 

Copyright 1999-2020 Zeroboard / skin by ROBIN